Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Viewpoint - Investors are expected to focus on Amicus Therapeutics' sales performance and updates regarding its merger with BioMarin Pharmaceutical during the upcoming earnings report for Q4 and full-year 2025 [1][6]. Sales Performance - The Zacks Consensus Estimate for Q4 sales is $179.9 million, with earnings expected at 13 cents per share [1]. - Galafold sales are projected to be a key revenue driver, with estimates for Q4 sales at $157 million, reflecting strong demand and compliance [8]. - The combination therapy Pombiliti + Opfolda is also expected to contribute positively to revenues, following its FDA approval in September 2023 [7][8]. Earnings Estimates - The Zacks Consensus Estimate for 2025 EPS is stable at 35 cents, while the estimate for 2026 is 65 cents [2]. - The earnings surprise history shows Amicus has beaten earnings expectations only once in the last four quarters, with an average negative surprise of 20.21% [4]. Merger Details - BioMarin has agreed to acquire Amicus for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [9][10]. - Post-acquisition, BioMarin will add Galafold and Pombiliti to its portfolio and gain exclusive U.S. rights to the late-stage drug DMX-200 [10]. Stock Performance - Amicus shares have increased by 104.9% over the past six months, outperforming the industry growth of 23.8% [11]. - The stock is currently trading at a price-to-sales (P/S) ratio of 7.42, which is higher than the industry average of 2.46, but below its five-year mean of 8.72 [14][15]. Investment Outlook - The acquisition by BioMarin is seen as a potential catalyst for value realization beyond organic sales growth, with optimism surrounding the strong sales of marketed products [16]. - Despite concerns regarding competition and reliance on Galafold, the company is expected to maintain growth potential, making it advisable for current investors to hold their positions [17][19].

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Amicus Therapeutics, Inc. tops our list for being one of the best biotech stocks. TheFly reported on January 22 that Jefferies downgraded FOLD to Buy from Hold and lowered the price target to $14.50 from $16. The company got substantial pharmaceutical takeover interest outside of BioMarin, according to proxy records, but Jefferies does not expect any more proposals. Jefferies Downgrades Amicus Therapeutics, Inc. (NASDAQ:FOLD) ...

Key Takeaways FOLD stands out after agreeing to a $14.50-per-share buyout by BioMarin, expected to be closed in Q2 2026.FOLD's Galafold drove over 80% of sales in 9M 2025, while Pombiliti plus Opfolda showed strong initial growth.RIGL's revenues are powered by Tavalisse, with added momentum from Rezlidhia and newly acquired Gavreto.Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL) appeal to growth-focused investors as they target rare diseases, where small patient populations can still support str ...

Group 1 - BioMarin Pharmaceutical (NASDAQ:BMRN) is identified as a promising large-cap stock under $100 with significant upside potential, with price targets revised upwards by analysts [1][3] - Canaccord Genuity analyst Whitney Ijem upgraded her rating from Hold to Buy and increased the price target from $84 to $98, indicating a potential upside of nearly 75% [1][2] - Truist Securities analyst Joon Lee also raised his price target from $80 to $100, suggesting a potential upside of approximately 78% while maintaining a Buy rating [3] Group 2 - Both analysts attribute their positive outlook to BioMarin's potential acquisition of Amicus Therapeutics, which is expected to be finalized in the second quarter of 2026 [4] - The acquisition is seen as strategically aligned with BioMarin's focus on rare diseases and its existing drug portfolio, particularly highlighting Amicus's approved drugs, Galafold and PomOp [4] - The deal is anticipated to be accretive within 12 months, further enhancing BioMarin's growth prospects [4] Group 3 - BioMarin specializes in developing and commercializing targeted therapies for life-threatening medical conditions and rare genetic diseases, with key products including VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME [5] - The company operates in over 70 countries and has a robust pipeline of drugs in various stages of development [5]

Core Insights - Amicus Therapeutics (FOLD) shares have surged 135.8% over the past six months, significantly outperforming the industry and the S&P 500 Index, driven by strong product momentum and a merger agreement with BioMarin Pharmaceutical (BMRN) [1][8]. Company Overview - BioMarin has agreed to acquire all outstanding shares of Amicus for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [3]. - Post-acquisition, BioMarin will integrate Amicus' marketed products, including Galafold (migalastat) and the combination therapy Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), both of which have shown steady sales growth [3][4]. Product Performance - Galafold generated sales of $371.5 million in the first nine months of 2025, accounting for over 80% of Amicus' net product sales, with a year-over-year growth of approximately 12% [6][9]. - Pombiliti + Opfolda achieved sales of $77.5 million in the same period, reflecting a 61% increase year-over-year, indicating strong market potential [10]. Competitive Landscape - Amicus faces significant competition in the lysosomal storage disorder market, particularly from established players like Sanofi and Takeda, which market therapies for Fabry disease and Pompe disease [11][12][13]. - The company's heavy reliance on Galafold for revenue poses a risk, especially with increasing competition [11]. Valuation and Estimates - Amicus shares are currently trading at a price-to-sales (P/S) ratio of 7.42, which is above the industry average of 2.51, but below its five-year mean of 8.82 [14]. - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has slightly increased from 34 cents to 35 cents, while estimates for 2026 have decreased from 67 cents to 65 cents [15]. Investment Outlook - The strong sales performance of Amicus' marketed products is expected to continue driving revenue growth, with incremental contributions from Pombiliti + Opfolda [17]. - Given the impending acquisition by BioMarin, investment strategies should focus on event-driven trading rather than long-term growth [18]. - Despite competitive risks, Amicus' unique positioning in the rare disease market and stable earnings estimates suggest a positive outlook, making it a potential addition for investors seeking short-term gains before the acquisition [19].

Core Insights - BioMarin Pharmaceutical is targeting a preliminary revenue of $3.2 billion for 2025, with Voxzogo expected to contribute $920 million, reflecting a strong performance and a projected 27% year-over-year growth in Q4 [3][6] - The company is focusing on expanding Voxzogo's market presence and enhancing its enzyme therapies portfolio, alongside the strategic acquisition of Amicus, valued at $4.8 billion, which is expected to diversify and accelerate revenue growth [7][8] Revenue and Growth Projections - BioMarin anticipates Voxzogo's growth in achondroplasia will be supported by new country launches and deeper market penetration, particularly emphasizing early treatment decisions for infants [2][6] - The acquisition of Amicus is expected to be accretive within 12 months post-close and substantially accretive starting in 2027, with confidence in outperforming previous growth expectations for enzyme therapies [8][7] Strategic Focus and Pipeline Development - The company's strategy is built on three pillars: innovation, growth, and a value commitment, prioritizing pipeline programs with transformative potential, including BMN 333 and BMN 351 [5][6] - BioMarin plans to accelerate revenue through geographic expansion of Voxzogo and potential label expansions for other therapies, including Palynziq [4][6] Clinical and Regulatory Catalysts - BioMarin is preparing to file for full approval of Voxzogo with the FDA, leveraging extensive safety data and additional efficacy endpoints [11] - Upcoming regulatory actions include an FDA PDUFA date for Palynziq's adolescent label expansion and significant data readouts for BMN 351 and BMN 333 [12][10][13] Competitive Dynamics and Intellectual Property Strategy - The company is committed to defending its intellectual property for Voxzogo, including seeking orphan drug exclusivity and engaging in ongoing litigation to protect its market position [15][16] - BioMarin views BMN 333 as a potential long-term game changer for achondroplasia, based on its promising exposure profile [16]

BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Event**: FY Conference held on January 12, 2026 - **CEO**: Alexander Hardy Key Industry Insights - BioMarin is a leader in genetically defined conditions with a strong track record of innovation, having six first-in-disease treatments and many best-in-disease treatments [6][7] - The company operates in 80 countries and has significant R&D capabilities and in-house manufacturing [6][7] Core Financial Highlights - Preliminary revenue for 2025 is projected at **$3.2 billion**, with a **15% CAGR** over the last two years [9][21] - Voxzogo, a treatment for achondroplasia, is expected to generate **$920 million** in revenue for 2025, reflecting a **27% year-over-year growth** [19][21] Strategic Pillars 1. **Innovation**: Focus on transformative potential in the pipeline, with key assets like 333 and 351 showing promise [8][12] 2. **Growth**: Significant growth rates driven by enzyme therapies and the expansion of Voxzogo into new indications and countries [9][10] 3. **Value Commitment**: Cost transformation efforts have identified **$500 million** in cost reductions, enhancing profitability and cash flow [10] Amicus Acquisition - BioMarin announced the acquisition of Amicus for an equity value of **$4.8 billion**, which is expected to enhance revenue growth and diversify the revenue base [14][15] - Key products from Amicus include: - **Galafold** for Fabry disease, currently available in **40 countries**, with plans to expand to BioMarin's **80-country footprint** [16][17] - **Pombiliti** for Pompe disease, currently reimbursed in **15 countries**, with potential for significant growth [18] Pipeline and R&D Updates - Upcoming catalysts include: - Filing for full approval of Voxzogo in achondroplasia [12][34] - Two phase 3 data readouts and label expansions expected within the year [12][24] - BMN 351 for Duchenne muscular dystrophy showing promising early results [24][25] - BMN 333 for achondroplasia demonstrating over **13-fold** increase in free CNP exposure [28] Market Position and Competition - BioMarin is focused on defending its market position for Voxzogo against potential competitors by leveraging its established safety profile and efficacy data [49][50] - The company has petitioned for orphan drug exclusivity to delay the approval of competing products for **three more years** [49] Future Outlook - BioMarin aims for sustained double-digit CAGR growth into the 2030s, supported by the integration of Amicus products and ongoing pipeline developments [22][37] - The company is optimistic about its ability to reach more patients and enhance treatment options through its expanded portfolio [15][51] Additional Notes - The adherence rate for Voxzogo is approximately **90%**, indicating strong patient retention [45] - The company emphasizes the importance of early diagnosis and treatment in achondroplasia, which is expected to drive future growth [39][40]

44th Annual J.P. Morgan Healthcare Conference Alexander Hardy Chief Executive Officer Greg Friberg Chief R&D Officer BioMarin Pharmaceutical Inc. January 12, 2026 These risks and uncertainties include, without limitations, risks relating to the completion of BioMarin's normal quarterly and annual accounting and financial statement closing procedures for the quarter and the year ended December 31, 2025; the timing of orders for commercial products; BioMarin's ability to meet product demand; risks and uncerta ...

Core Insights - Amicus Therapeutics has made significant progress with its lead product, Galafold, which is crucial for the company's revenue generation [1][2] - Galafold is approved for treating Fabry disease and has been a major contributor to Amicus' sales performance [1][2] Sales Performance - In the first nine months of 2025, Galafold generated sales of $371.5 million, reflecting a year-over-year increase of approximately 12% [2][9] - Galafold accounted for over 80% of Amicus' net product sales during this period [2][9] - The combination therapy Pombiliti + Opfolda generated $77.5 million in sales, up around 61% year-over-year [6][9] Market Position and Competition - Galafold benefits from a strong intellectual property portfolio in the U.S., with patent protection extending through 2038 [3][9] - The recent settlement with Teva Pharmaceuticals prevents the sale of a generic version of Galafold in the U.S. until January 2037, which is expected to support sales growth [4][6] - Amicus faces competition from established players like Sanofi and Takeda, which market products for treating Fabry disease and other lysosomal storage disorders [7][8] Financial Metrics and Valuation - Amicus shares have increased by 135.6% over the past six months, outperforming the industry growth of 21.5% [10] - The company's price-to-sales (P/S) ratio is currently 7.39, significantly higher than the industry average of 2.43, although it is below its five-year mean of 8.89 [12] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen from 31 cents to 35 cents over the past 60 days, while estimates for 2026 have decreased from 70 cents to 65 cents [13]